WO2012023113A3 - Designer osteogenic proteins - Google Patents

Designer osteogenic proteins Download PDF

Info

Publication number
WO2012023113A3
WO2012023113A3 PCT/IB2011/053638 IB2011053638W WO2012023113A3 WO 2012023113 A3 WO2012023113 A3 WO 2012023113A3 IB 2011053638 W IB2011053638 W IB 2011053638W WO 2012023113 A3 WO2012023113 A3 WO 2012023113A3
Authority
WO
WIPO (PCT)
Prior art keywords
designer
osteogenic proteins
novel
designer osteogenic
cognate
Prior art date
Application number
PCT/IB2011/053638
Other languages
French (fr)
Other versions
WO2012023113A2 (en
Inventor
Stephen Peter Berasi
Christopher Todd Brown
Michael John Cain
Valerie Perrine Calabro
Zong Sean Juo
Robert Vincent Paul Martinez
Howard Joel Seeherman
John Martin Wozney
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44720059&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2012023113(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to BR112013003587-0A priority Critical patent/BR112013003587B1/en
Priority to EP11763772.8A priority patent/EP2605787B1/en
Priority to KR1020177021849A priority patent/KR101800596B1/en
Priority to AU2011292810A priority patent/AU2011292810B2/en
Priority to EP17209849.3A priority patent/EP3320913B1/en
Priority to SG2013005285A priority patent/SG187589A1/en
Priority to KR1020137006970A priority patent/KR101630501B1/en
Priority to KR1020167012916A priority patent/KR101767860B1/en
Priority to MX2013001977A priority patent/MX2013001977A/en
Priority to JP2013525388A priority patent/JP5985480B2/en
Priority to RU2013104029/10A priority patent/RU2013104029A/en
Priority to CA2807343A priority patent/CA2807343C/en
Priority to CN201180040389.7A priority patent/CN103079585B/en
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of WO2012023113A2 publication Critical patent/WO2012023113A2/en
Publication of WO2012023113A3 publication Critical patent/WO2012023113A3/en
Priority to IL224394A priority patent/IL224394A/en
Priority to HK13111831.5A priority patent/HK1184377A1/en
Priority to AU2015202418A priority patent/AU2015202418B2/en
Priority to AU2017200239A priority patent/AU2017200239B2/en
Priority to IL254186A priority patent/IL254186A0/en
Priority to IL261608A priority patent/IL261608B/en
Priority to AU2018236821A priority patent/AU2018236821B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor, nucleic acids encoding the same, and methods of use therefor. More preferably, the novel designer osteogenic proteins are designer BMPs and have altered affinity for a cognate BMP receptor. The designer BMPs demonstrate altered biological characteristics and provide potential useful novel therapeutics.
PCT/IB2011/053638 2010-08-20 2011-08-17 Designer osteogenic proteins WO2012023113A2 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
EP11763772.8A EP2605787B1 (en) 2010-08-20 2011-08-17 Designer osteogenic proteins
CA2807343A CA2807343C (en) 2010-08-20 2011-08-17 Designer osteogenic proteins
RU2013104029/10A RU2013104029A (en) 2010-08-20 2011-08-17 DESIGNED OSTEOGENIC PROTEINS
AU2011292810A AU2011292810B2 (en) 2010-08-20 2011-08-17 Designer osteogenic proteins
EP17209849.3A EP3320913B1 (en) 2010-08-20 2011-08-17 Designer osteogenic proteins
SG2013005285A SG187589A1 (en) 2010-08-20 2011-08-17 Designer osteogenic proteins
KR1020137006970A KR101630501B1 (en) 2010-08-20 2011-08-17 Designer osteogenic proteins
KR1020167012916A KR101767860B1 (en) 2010-08-20 2011-08-17 Designer osteogenic proteins
MX2013001977A MX2013001977A (en) 2010-08-20 2011-08-17 Designer osteogenic proteins.
CN201180040389.7A CN103079585B (en) 2010-08-20 2011-08-17 Through the BMP of design
KR1020177021849A KR101800596B1 (en) 2010-08-20 2011-08-17 Designer osteogenic proteins
BR112013003587-0A BR112013003587B1 (en) 2010-08-20 2011-08-17 ENGINEERED OSTEOGENIC PROTEINS, THEIR USES, THEIR METHOD OF PRODUCTION AND ISOLATED NUCLEIC ACID MOLECULE
JP2013525388A JP5985480B2 (en) 2010-08-20 2011-08-17 Designer bone morphogenetic protein
IL224394A IL224394A (en) 2010-08-20 2013-01-24 Designer osteogenic proteins
HK13111831.5A HK1184377A1 (en) 2010-08-20 2013-10-22 Designer osteogenic proteins
AU2015202418A AU2015202418B2 (en) 2010-08-20 2015-05-06 Designer osteogenic proteins
AU2017200239A AU2017200239B2 (en) 2010-08-20 2017-01-13 Designer osteogenic proteins
IL254186A IL254186A0 (en) 2010-08-20 2017-08-28 Designer osteogenic proteins
IL261608A IL261608B (en) 2010-08-20 2018-09-05 Designer osteogenic proteins
AU2018236821A AU2018236821B2 (en) 2010-08-20 2018-09-27 Designer osteogenic proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37563610P 2010-08-20 2010-08-20
US61/375,636 2010-08-20

Publications (2)

Publication Number Publication Date
WO2012023113A2 WO2012023113A2 (en) 2012-02-23
WO2012023113A3 true WO2012023113A3 (en) 2012-04-12

Family

ID=44720059

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2011/053638 WO2012023113A2 (en) 2010-08-20 2011-08-17 Designer osteogenic proteins

Country Status (18)

Country Link
US (1) US8952131B2 (en)
EP (4) EP2949338B1 (en)
JP (4) JP5985480B2 (en)
KR (3) KR101767860B1 (en)
CN (2) CN103079585B (en)
AR (1) AR082502A1 (en)
AU (1) AU2011292810B2 (en)
BR (1) BR112013003587B1 (en)
CA (1) CA2807343C (en)
CO (1) CO6680686A2 (en)
HK (1) HK1184377A1 (en)
IL (3) IL224394A (en)
MX (1) MX2013001977A (en)
PE (1) PE20140135A1 (en)
RU (1) RU2013104029A (en)
SG (1) SG187589A1 (en)
TW (1) TWI444475B (en)
WO (1) WO2012023113A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9688735B2 (en) * 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
EP2602264A1 (en) 2011-12-05 2013-06-12 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH GDF-5 mutant for inducing cartilage formation
EP2784083A1 (en) * 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
US9872881B2 (en) * 2013-11-01 2018-01-23 The Brigham And Women's Hospital, Inc. Bone and metal targeted polymeric nanoparticles
CA2977625A1 (en) 2014-12-29 2016-07-07 Bioventus, Llc Systems and methods for improved delivery of osteoinductive molecules in bone repair
BR112017021484A2 (en) 2015-06-05 2018-07-03 Novartis Ag antibodies targeting bone morphogenetic protein 9 (bmp9) and methods for them
EP3341397A2 (en) * 2015-08-25 2018-07-04 Histide AG Compounds for inducing tissue formation and uses thereof
AU2016311298A1 (en) 2015-08-25 2018-02-08 Histide Ag Compounds for inducing tissue formation and uses thereof
CA3002404A1 (en) 2015-10-23 2017-04-27 Bioventus, Llc Improved purification of tgf-beta superfamily proteins
US20170319750A1 (en) 2016-05-09 2017-11-09 Bioventus, Llc Composite matrices designed for enhanced bone repair
AU2017278294A1 (en) * 2016-06-10 2018-12-20 Bioventus, Llc Protein delivery with porous metallic structure
TWI806385B (en) 2016-07-20 2023-06-21 瑞士商諾華公司 Aminopyridine derivatives and their use as selective alk-2 inhibitors
CN106749606B (en) * 2016-12-29 2018-06-22 广州领晟医疗科技有限公司 A kind of peptide for repairing cartilage and/or treating osteoarthritis
US10919948B2 (en) 2016-12-30 2021-02-16 Biogend Therapeutics Co., Ltd. Recombinant polypeptides, compositions, and methods thereof
WO2019102256A1 (en) 2017-11-24 2019-05-31 Novartis Ag Pyridinone derivatives and their use as selective alk-2 inhibitors
US11529438B2 (en) 2018-06-25 2022-12-20 Bioventus, Llc Porous carrier matrix

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1571159A1 (en) * 2004-03-04 2005-09-07 Bayerische Julius-Maximilians-Universität Würzburg Mutein of a bone morphogenetic protein and use thereof
WO2008051526A2 (en) * 2006-10-23 2008-05-02 Stryker Corporation Bone morphogenetic proteins
WO2009086131A1 (en) * 2007-12-21 2009-07-09 Stryker Corporation Bmp mutants with decreased susceptibility to noggin

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (en) 1985-06-19 1990-12-20 Ajinomoto Kk HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE).
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5459047A (en) 1986-07-01 1995-10-17 Genetics Institute, Inc. BMP-6 proteins
ZA874681B (en) 1986-07-01 1988-04-27 Genetics Inst Novel osteoinductive factors
US6432919B1 (en) 1986-07-01 2002-08-13 Genetics Institute, Inc. Bone morphogenetic protein-3 and compositions
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
US5543394A (en) 1986-07-01 1996-08-06 Genetics Institute, Inc. Bone morphogenetic protein 5(BMP-5) compositions
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5266683A (en) 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5688678A (en) 1990-05-16 1997-11-18 Genetics Institute, Inc. DNA encoding and methods for producing BMP-8 proteins
CA2085134C (en) 1990-06-15 2003-03-18 Carnegie Institution Of Washington Gdf-1
US5849686A (en) 1991-03-11 1998-12-15 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
US5656593A (en) 1991-03-11 1997-08-12 Creative Biomolecules, Inc. Morphogen induced periodontal tissue regeneration
US5674844A (en) 1991-03-11 1997-10-07 Creative Biomolecules, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US6506729B1 (en) 1991-03-11 2003-01-14 Curis, Inc. Methods and compositions for the treatment and prevention of Parkinson's disease
US5652337A (en) 1991-03-11 1997-07-29 Creative Biomolecules, Inc. OP-3-induced morphogenesis
US6949505B1 (en) 1991-03-11 2005-09-27 Curis, Inc. Morphogen-induced dendritic growth
US6800603B2 (en) 1991-03-11 2004-10-05 Curis, Inc. Morphogen-induced neural cell adhesion
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
US6025475A (en) 1998-09-15 2000-02-15 The Johns Hopkins University School Of Medicine Growth differentiation factor-3
EP1333035A3 (en) 1993-03-19 2004-07-07 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
EP1378572B1 (en) 1993-05-12 2006-10-25 Genetics Institute, LLC Bmp-11 compositions
US5637480A (en) 1993-05-12 1997-06-10 Genetics Institute, Inc. DNA molecules encoding bone morphogenetic protein-10
IL110589A0 (en) 1993-08-10 1994-11-11 Bioph Biotech Entw Pharm Gmbh Growth/differentiation factor of the TGF- beta family
US6204047B1 (en) 1993-10-08 2001-03-20 The Johns Hopkins University School Of Medicine Growth differentiation factor-10
US6027919A (en) 1993-12-07 2000-02-22 Genetics Institute, Inc. BMP-12 and BMP-13 proteins and DNA encoding them
US5733757A (en) 1995-12-15 1998-03-31 The Scripps Research Institute Aldolase catalytic antibody
US5635372A (en) 1995-05-18 1997-06-03 Genetics Institute, Inc. BMP-15 compositions
CA2249368A1 (en) 1996-03-22 1997-09-25 The General Hospital Corporation Administration of polypeptide growth factors following central nervous system ischemia or trauma
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
US5965403A (en) 1996-09-18 1999-10-12 Genetics Institute, Inc. Nucleic acids encoding bone morphogenic protein-16 (BMP-16)
US7601685B2 (en) 1998-08-27 2009-10-13 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
US7572440B2 (en) 1999-07-30 2009-08-11 Stryker Corporation Method for repairing a defect in an intervertebral disc
US6846906B1 (en) 1998-10-07 2005-01-25 Stryker Corporation Modified proteins of the TGF-β superfamily, including morphogenic proteins
EP1117805A2 (en) * 1998-10-07 2001-07-25 STRYKER CORPORATION (a Michigan corporation) Modified tgf-beta superfamily proteins
ES2209820T3 (en) 1999-02-04 2004-07-01 Sdgi Holdings, Inc. HIGHLY MINERALIZED OSTEOGENIC SPONGE COMPOSITIONS, AND USES OF THE SAME.
US7435260B2 (en) 1999-08-13 2008-10-14 Ferree Bret A Use of morphogenetic proteins to treat human disc disease
DE10026713A1 (en) 2000-05-30 2001-12-06 Walter Sebald Mutein a chain of a protein from the superfamily of the growth factor TGF-beta
EP1335686B1 (en) 2000-10-24 2008-12-17 Warsaw Orthopedic, Inc. Spinal fusion devices
US7459527B2 (en) * 2004-03-31 2008-12-02 Xencor, Inc. BMP-7 variants with improved properties
EP1740609A2 (en) 2004-04-27 2007-01-10 Research Development Foundation Antagonism of tgf-beta superfamily receptor signaling
WO2005113585A2 (en) 2004-05-20 2005-12-01 Acceleron Pharma Inc. Modified tgf-beta superfamily polypeptides
US7749268B2 (en) 2004-05-26 2010-07-06 Warsaw Orthopedic, Inc. Methods for treating the spine
AU2005250441A1 (en) 2004-05-27 2005-12-15 Acceleron Pharma Inc. TGF derepressors and uses related thereto
CA2569509C (en) 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
WO2006069331A2 (en) 2004-12-22 2006-06-29 The Salk Institute For Biological Studies Compositions and methods for producing recombinant proteins
WO2006125868A1 (en) 2005-05-27 2006-11-30 Bbs-Bioactive Bone Substitutes Oy Bone morphogenetic proteins containing a heparin binding site and osteogenic devices and pharmaceutical products containing thereof
US7671014B2 (en) 2006-08-14 2010-03-02 Warsaw Orthopedic, Inc. Flowable carrier matrix and methods for delivering to a patient
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
GB0818255D0 (en) * 2008-10-06 2008-11-12 Agency Science Tech & Res Isolation and identification of glycosaminoglycans
CA2752647A1 (en) 2009-02-24 2010-09-02 The Salk Institute For Biological Studies Designer ligands of tgf-beta superfamily
WO2011025042A1 (en) 2009-08-31 2011-03-03 新日本製鐵株式会社 High-strength hot-dip galvanized steel sheet and process for producing same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1571159A1 (en) * 2004-03-04 2005-09-07 Bayerische Julius-Maximilians-Universität Würzburg Mutein of a bone morphogenetic protein and use thereof
WO2008051526A2 (en) * 2006-10-23 2008-05-02 Stryker Corporation Bone morphogenetic proteins
WO2009086131A1 (en) * 2007-12-21 2009-07-09 Stryker Corporation Bmp mutants with decreased susceptibility to noggin

Also Published As

Publication number Publication date
KR101767860B1 (en) 2017-08-14
KR101800596B1 (en) 2017-11-22
AR082502A1 (en) 2012-12-12
WO2012023113A2 (en) 2012-02-23
IL261608B (en) 2019-05-30
KR20160062191A (en) 2016-06-01
EP3124039B1 (en) 2018-01-31
AU2011292810B2 (en) 2015-04-30
JP2016196478A (en) 2016-11-24
JP2018126148A (en) 2018-08-16
IL261608A (en) 2018-10-31
JP5985480B2 (en) 2016-09-06
CN105198981B (en) 2019-07-16
EP2605787A2 (en) 2013-06-26
RU2013104029A (en) 2014-09-27
KR20130048782A (en) 2013-05-10
JP6142041B2 (en) 2017-06-07
IL224394A (en) 2017-11-30
EP3124039A2 (en) 2017-02-01
CN105198981A (en) 2015-12-30
BR112013003587A2 (en) 2016-06-07
IL254186A0 (en) 2017-10-31
CO6680686A2 (en) 2013-05-31
EP3124039A3 (en) 2017-03-08
HK1184377A1 (en) 2014-01-24
SG187589A1 (en) 2013-03-28
EP3320913A3 (en) 2018-07-25
BR112013003587A8 (en) 2017-12-26
CN103079585A (en) 2013-05-01
CN103079585B (en) 2015-09-30
EP3320913A2 (en) 2018-05-16
BR112013003587B1 (en) 2022-11-08
TW201226565A (en) 2012-07-01
EP3320913B1 (en) 2019-11-27
US20120046227A1 (en) 2012-02-23
US8952131B2 (en) 2015-02-10
EP2949338A1 (en) 2015-12-02
CA2807343A1 (en) 2012-02-23
MX2013001977A (en) 2013-04-03
EP2949338B1 (en) 2017-10-25
TWI444475B (en) 2014-07-11
CA2807343C (en) 2018-05-22
AU2011292810A1 (en) 2013-02-07
JP2017029143A (en) 2017-02-09
KR101630501B1 (en) 2016-06-15
JP6317789B2 (en) 2018-04-25
KR20170094549A (en) 2017-08-18
EP2605787B1 (en) 2017-04-26
PE20140135A1 (en) 2014-02-20
JP2013538054A (en) 2013-10-10

Similar Documents

Publication Publication Date Title
WO2012023113A3 (en) Designer osteogenic proteins
IL250938A0 (en) Enzymatic fusion proteins, compositions comprising the same and uses thereof
WO2013006953A8 (en) Genes and proteins for alkanoyl-coa synthesis
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
BRPI1013688A2 (en) il-17 binding proteins.
FR2945538B1 (en) HUMANIZED ANTIBODIES SPECIFIC TO THE PROTOFIBRILLARY FORM OF THE BETA-AMYLOID PEPTIDE.
WO2009149956A3 (en) Fusion protein and use thereof
WO2013138793A3 (en) Affinity reagants for protein purification
HK1215954A1 (en) Btnl9 proteins, nucleic acids, and antibodies and uses thereof btnl9
GB0922209D0 (en) Proteins, nucleic acid molecules and compositions
WO2012064836A9 (en) Methods and compositions for neural disease immunotherapy
CA2705357C (en) Formulations for taci-immunoglobulin fusion proteins
NL2000380A1 (en) 3-aminocyclopentane carboxamides as modulators of chemokine receptors.
WO2011147762A3 (en) Stabilized radiopharmaceutical composition
GB0922113D0 (en) Protein stabilizer
WO2007045019A3 (en) Polyoleosins
IT1392200B1 (en) MODULAR VERTEBRAL STABILIZER.
FR2939766B1 (en) CENTRAL PYLONE OF AIRCRAFT.
WO2009149218A3 (en) Novel proteins and methods of designing and using same
BR112012014495A2 (en) self-leveling cosmetic.
BRPI0822347A2 (en) method of producing heterologous proteins or peptides.
FR2913338B1 (en) REHYDRATION COMPOSITION.
WO2010111421A3 (en) Isoform nell-1 peptide
WO2009003732A3 (en) Peptides with high affinity for the prolactin receptor
BRPI0910322A2 (en) silica silica suspension use and pharmaceutical composition

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180040389.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11763772

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 224394

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2807343

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2011292810

Country of ref document: AU

Date of ref document: 20110817

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12013500294

Country of ref document: PH

REEP Request for entry into the european phase

Ref document number: 2011763772

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/001977

Country of ref document: MX

Ref document number: 2011763772

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2013525388

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 000312-2013

Country of ref document: PE

WWE Wipo information: entry into national phase

Ref document number: 13041042

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 20137006970

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2013104029

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013003587

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013003587

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130215